U.S., Aug. 30 -- ClinicalTrials.gov registry received information related to the study (NCT07148310) titled 'Hepatocellular Carcinoma Identification Using Delta-HLD' on Aug. 22.
Brief Summary: HIDE (Hepatocellular Carcinoma Identification via Delta-HLD) is a proof-of-concept case-control study designed to evaluate the performance of delta-HLD, Epiliquid's proprietary liquid biopsy technology, in detecting hepatocellular carcinoma (HCC). The study includes both plasma and tissue samples to assess biomarker concordance and evaluate diagnostic sensitivity and specificity using tumor-specific methylation markers detected by PCR.
Study Start Date: May 18, 2023
Study Type: OBSERVATIONAL
Condition:
Hepato Cellular Carcinoma (HCC)
Recruitment...